Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/22620
Title: Variation in the Use of Single- Versus Multifraction Palliative Radiation Therapy for Bone Metastases in Australia.
Authors: Ong, Wee Loon;Foroudi, Farshad;Milne, Roger L;Millar, Jeremy L
Affiliation: Health and Biomedical Informatics Centre, The University of Melbourne, Melbourne, Australia
Precision Medicine, School of Clinical Sciences, Monash Health, Monash University, Melbourne, Australia
School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdon
Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia
Department of Radiation Oncology, Austin Health, Heidelberg, Victoria, Australia
Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia
Alfred Health Radiation Oncology Services, Prahran, Australia
Central Clinical School, Monash University, Melbourne, Australia
Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia
Centre for Epidemiology and Biostatistics, School of Population and Global Health, The University of Melbourne, Melbourne, Australia
Issue Date: 1-Jan-2020
EDate: 2019
Citation: International journal of radiation oncology, biology, physics 2020; 106(1): 61-66
Abstract: To evaluate the use of single-fraction palliative radiation therapy (SFRT) for the management of bone metastases (BM) in Victoria, Australia. This is a population-based cohort of patients with cancer who received radiation therapy for BM between 2012 and 2017 as captured in the Victorian Radiotherapy Minimum Data Set. The primary outcome was proportion of SFRT use. The Cochrane-Armitage test for trend was used to evaluate changes in practice over time. Multivariable logistic regression was used to assess factors associated with SFRT use. Of the 18,158 courses of radiation therapy for BM delivered to a total of 10,956 patients, 17% were SFRT. There was no significant change in SFRT use over time, from 18% in 2012 to 19% in 2017 (P = .07). SFRT was less commonly given to the skull (4%) and spine (14%), compared with the shoulder (37%) and ribs (53%). Patients with lung cancer (21%) were most likely to receive SFRT, followed by those with prostate cancers (18%) and gastrointestinal cancers (16%). Patients from regional/remote areas were more likely to have SFRT compared with those in major cities (22% vs 16%, P < .001). Patients treated in public institutions were more likely to have SFRT compared with those treated in private institutions (22% vs 10%, P < .001). In multivariable analyses, increasing age, lung cancer, higher socioeconomic status, residence in regional/ remote areas, and being treated in public institutions were factors independently associated with increased likelihood of receiving SFRT. SFRT appears underused for BM in Australia over time, with variation in practice by patient, tumor, sociodemographic, geographical, and institutional provider factors.
URI: http://ahro.austin.org.au/austinjspui/handle/1/22620
DOI: 10.1016/j.ijrobp.2019.08.061
ORCID: 0000-0001-8387-0965
0000-0001-6657-7193
PubMed URL: 31505246
Type: Journal Article
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.